Central Alerting System
View Alert

Originator: National Patient Safety Alert - DHSC

Issue date: 27-Sep-2023 13:28:35

This alert has been issued to:
  • Care Trusts
  • Mental Health Trusts
  • Specialists Trusts
  • Learning Disabilities Trusts
  • Mental Health & Social Care Trusts
  • Ambulance Trusts
  • Mental Health & Learning Disabilities Trusts
  • Acute Trusts
  • Community Trusts

  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Regional Offices
  • Social Care Providers (registered with CAS)
  • Special Health Authorities
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Director of Public Health
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • DHSC Supply Disruption - Medicines
  • Community Pharmacy
  • Primary Care Networks
  • GP Practices 1

Action category: Action

Title: Shortage of methylphenidate prolonged-release capsules and tablets, lisdexamfetamine capsules, and guanfacine prolonged-release tablets

Broadcast content:

There are supply disruptions affecting various strengths of the following medications which are licensed for the treatment of attention deficit hyperactivity disorder (ADHD):

·       Methylphenidate:

·       Equasym XL® 10, 20 and 30 mg capsules

·       Xaggitin XL® 18 and 36 mg prolonged-release tablets

·       Concerta XL® 54 mg prolonged-release tablets

·       Xenidate XL® 27 mg prolonged-release tablets

·       Lisdexamfetamine: 

·       Elvanse® 20, 30, 40, 50, 60 and 70 mg capsules

·       Elvanse® Adult 30, 50, and 70 mg capsules

·       Guanfacine:

·       Intuniv® 1, 2, 3 and 4 mg prolonged-release tablets


The supply disruption of these products is caused by a combination of manufacturing issues and an increased global demand.

Other ADHD products remain available but cannot meet excessive increases in demand.

At present, the supply disruptions are expected to resolve at various dates between October and December 2023.

This National Patient Safety Alert provides further background and clinical information and actions for providers.

Additional information: NHS England Regions: please cascade this alert to community pharmacy

Alert reference: NatPSA/2023/011/DHSC

Action underway deadline: 29-Sep-2023

Action complete deadline: 11-Oct-2023


Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency